News

FDA approves alogliptin, alone and in combinations

Publish date: January 28, 2013

 

a.ault@elsevier.com

Twitter @aliciaault

Pages

Recommended Reading

Dalcetrapib Boosts HDL Without Benefiting Patients
MDedge Cardiology
Ranbaxy Recalls Atorvastatin
MDedge Cardiology
PCSK9 Antibodies Safely Cut LDL in Phase II
MDedge Cardiology
Statins' Diabetogenic Impact Influenced by Underlying Risks
MDedge Cardiology
Bariatric surgery cut vascular events in diabetes
MDedge Cardiology
FDA panel backs approval of canagliflozin for type 2 diabetes
MDedge Cardiology
SSRIs for PTSD bring cardiometabolic benefits
MDedge Cardiology
How to prevent 1 million coronary events
MDedge Cardiology
Statins cut risk of hepatocellular carcinoma
MDedge Cardiology
HDL-raising: A good hypothesis gone bad
MDedge Cardiology